Ikano developed Nayzilam® (midazolam) nasal spray CIV, a benzodiazepine indicated for the acute treatment of intermittent stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient’s usual seizure pattern in patients with epilepsy 12+ years of age.